Cellazon

Accelerating Pathobiology-Driven Therapeutic Development with Arda Therapeutics  Cellazon, a TechBio therapeutics company is redefining drug discovery through deep understanding of cell-to-cell interactions and pathway detection. We are excited to share the success of our collaboration with Arda Therapeutics, where Cellazon’s PathwayPersona™ platform played a role in accelerating therapeutic development for Idiopathic Pulmonary Fibrosis (IPF). PathwayPersona™ leveraged state-of-the-art spatial transcriptomics data, directly from patient biopsies, to uncover disease-causing cellular pathways and successfully validated pathogenic cell populations. Unlike traditional single-cell RNA-seq, which lack spatial context, this approach reveals how spatially distinct cell states contribute to IPF progression. Arda Therapeutics is proceeding to identify optimal surface proteins that could be used to eliminate these target pathogenic cell populations for therapeutic treatment of IPF.  As we expand our collaborative network and resource base, we welcome partners interested in translating patient biology into real therapeutic breakthroughs.

Advancing HIV Research with Gladstone Institutes Through Cellazon’s AI-Assisted PathwayPersona™ Platform Cellazon, a TechBio therapeutics company redefining drug discovery through deep understanding of cell-to-cell interactions and pathway detection, is proud to help advance HIV research. In collaboration with Dr. Nadia Roan at the Gladstone Institutes/University of California, San Francisco, Cellazon’s PathwayPersona™ platform played a key role in uncovering new insights into how certain individuals can naturally suppress HIV in the absence of antiretroviral therapy. By integrating single-cell RNA sequencing and ATAC-seq data directly from patient samples, PathwayPersona™ enabled the Gladstone team to go beyond validating existing hypotheses — revealing previously unknown cell communication pathways involved in post-treatment HIV control. These novel pathways, once validated, could potentially help improve HIV therapies and even lead to ways to elicit immune-mediated control of HIV in the absence of antiretroviral therapy.   As we expand our collaborative network and resource base, we welcome partners interested in translating patient biology into real therapeutic breakthroughs.

🎉 We are excited to welcome Dr. Yasin Şenbabaoğlu to Cellazon’s SAB! Yasin is the Computational Biology Platform Leader at Chan Zuckerberg Biohub San Francisco, where he oversees the efforts to develop machine learning models that decode and predict cellular behavior in health and disease. He brings deep expertise in single-cell genomics, cancer immunology, and systems biology, along with a proven track record of translating computational insights into therapeutic opportunities. With experience spanning Genentech, Memorial Sloan Kettering Cancer Center, and major NIH consortia, and with over 40k citations to his research, Yasin has advanced the fields of precision oncology, immuno-oncology biomarker discovery, and multi-omics target identification. We are thrilled to have Yasin’s expertise guiding Cellazon as we build our differentiated discovery platform and therapeutic pipeline.

✨ We are pleased to welcome Hareem Maune as our new Vice President of Strategy & Development! Hareem is an accomplished commercial leader with a strong technical background and over 15 years of experience developing and bringing innovative products to market. Her career spans global industry-leading organizations and high-growth startups, with expertise across multiple sectors including life science tools and nanomedicine. Her leadership and vision will play a key role in shaping Cellazon’s growth strategy and advancing our mission to systematically discover novel cell signaling pathways for therapeutic target and biomarker discovery.

Baback Gharizadeh is #hiring. Know anyone who might be interested?

🎉 We’re excited to welcome Dr. Changhan He to Cellazon’s Scientific Advisory Board! Dr. He is an Assistant Professor in the Department of Mathematics at the University of South Carolina. His work sits at the cutting edge of multiscale mathematical modeling and single-cell omics-driven inference, with a focus on cell–cell communication and cell fate transitions. At Cellazon, we’re on a mission to uncover therapeutic targets by reconstructing signaling pathways from complex omics data. Dr. He’s expertise in combining theoretical modeling, machine learning, and quantitative biology brings deep insight to our efforts to decode disease mechanisms and accelerate cell therapy development.

🎉 It’s our pleasure to welcome Dr. James Trager to Cellazon’s Scientific Advisory Board! Dr. Trager is a seasoned biotechnology leader with over 25 years of experience driving innovation in cancer and autoimmune disease therapies. A recognized expert in cellular therapies, he has played a critical role in advancing multiple programs from discovery through early clinical development. As Chief Scientific Officer at Nkarta Therapeutics, Dr. Trager led two CAR NK programs from concept to IND and early trials, while managing a team of over 100 scientists and engineers. He previously held senior leadership roles at Dendreon Pharmaceuticals, where he supported the development and commercialization of sipuleucel-T, and contributed to landmark discoveries in telomerase biology at Geron Corporation. Dr. Trager brings invaluable scientific and strategic insight as Cellazon continues its mission to decode disease-related cell–cell communication and accelerate the discovery of transformative therapies.

🎉 We are thrilled to welcome Dr. John Quackenbush to our Scientific Advisory Board! John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and a Professor at the Dana-Farber Cancer Institute. John explores how genes interact to drive complex phenotypes and how variables such as sex and gender shape gene regulatory networks. A pioneer in systems biology, he brings a unique blend of physics, genomics, and computational expertise. John has been widely recognized for his contributions to systems biology and computational genomics, including being named a White House Open Science Champion of Change in 2013. He founded Genospace, a precision medicine software company acquired by Hospital Corporation of America in 2017, and was elected to the National Academy of Medicine in 2022. John’s strategic guidance will be invaluable as we continue uncovering causal signaling pathways to advance precision therapies.

🎉 We’re excited to welcome Dr. Qing Nie to our Scientific Advisory Board! Dr. Nie is a Distinguished Professor of Mathematics and Developmental & Cell Biology at UC Irvine and holds the UC Presidential Chair. As Director of the NSF-Simons Center for Multiscale Cell Fate Research, he is internationally recognized for his pioneering work in systems biology, computational modeling, and single-cell dynamics. His deep expertise will be invaluable as we continue to advance our mission of uncovering complex signaling mechanisms to drive therapeutic discovery.